Nevada Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

TL;DR — What Nevada Medicaid Actually Covers

Nevada Is Not on the KFF “Covering” List

Unlike Washington Apple Health — which is classified by KFF as covering GLP-1s for obesity despite a clear operational exclusion — Nevada Medicaid is straightforward: KFF’s January 2026 tracker does NOT list Nevada among the covering states. The record is unambiguous.

A subtler misconception: some patients assume that because Wegovy has FDA approval for cardiovascular risk reduction AND Nevada Medicaid covers it for that indication, Wegovy must therefore also be accessible for weight loss through Nevada Medicaid. It is not. The Web Announcement 3337 carve-out is exclusively gated on the MACE indication. A patient with obesity and no established cardiovascular disease has no Wegovy pathway through Nevada Medicaid, regardless of BMI. A patient with T2DM and established CVD also has no Wegovy pathway — the PA criteria explicitly require absence of T1DM and T2DM.

For broader context, see GLP-1 insurance coverage across Medicare, Medicaid, and commercial plans.

Pharmacy Manual § 3.7 Categorical Exclusion

The operational anchor for Nevada Medicaid’s GLP-1 weight-loss exclusion is Section 3.7 of the Nevada Medicaid and Nevada Check Up Pharmacy Manual (“Covered and Non-Covered Drugs”), administered by Prime Therapeutics. Verbatim:

“The Nevada Medicaid Drug Rebate Program will not reimburse for the following pharmaceuticals:

• Agents used for weight loss
• Agents used to promote fertility
• Agents used for cosmetic purposes or hair growth
• Yohimbine
• Drug Efficacy Study and Implementation (DESI) list ‘Less than Effective Drugs’
• Pharmaceuticals considered ‘Experimental’ as to substance or diagnosis for which prescribed
• Pharmaceuticals manufactured by companies not participating in the federal Medicaid Drug Rebate Program unless rated ‘1-A’ by the FDA
• Agents used for impotence/erectile dysfunction”

Source: Nevada Medicaid and Nevada Check Up Pharmacy Manual, Section 3.7, administered by Prime Therapeutics Management LLC. Verified May 2026.

The phrase “Agents used for weight loss” is the categorical bar. This phrasing is operationally narrower than the federal authority at 42 U.S.C. § 1396r-8(d)(2)(A)(“Agents when used for anorexia, weight loss, or weight gain”) — Nevada omits “anorexia” and “weight gain” from its exclusion language. The practical effect: the exclusion applies exclusively to weight-loss-purpose use. Agents prescribed for non-weight-loss indications (e.g., Wegovy for MACE cardiovascular risk reduction) are not captured by the exclusion and require a separate coverage determination.

Unlike Oklahoma’s OAC 317:30-5-72.1(1)(D) (which builds in “unless otherwise specified” carve-out language) and Alabama’s Ala. Admin. Code r. 560-X-16-.01(2)(b) (which is a regulatory-level exclusion), Nevada’s exclusion is in the Pharmacy Manual — operationally below the regulatory level but directly binding on the Prime Therapeutics PBM for claims adjudication. The Wegovy MACE carve-out operates not by exception language in § 3.7 but by regulatory characterization: Wegovy prescribed for MACE is not “used for weight loss.”

Single PDL Omission of Wegovy, Zepbound, Saxenda, and Foundayo

The Nevada Medicaid Single Preferred Drug List (sPDL), effective November 1, 2025 (extended to statewide January 1, 2026 alignment per Web Announcement 3787, December 10, 2025), confirms the categorical exclusion operationally: the sPDL contains no anti-obesity drug class. The PDL header states verbatim:

“Nevada Medicaid’s PDL only includes select drug classes.”

The 148B Incretin Mimetics and Combinations class (under Hormones and Hormone Modifiers) contains only T2DM-indicated agents:

Source: Nevada Medicaid Single PDL, Section 148B Incretin Mimetics and Combinations, effective November 1, 2025. Verbatim from nv.primetherapeutics.com, verified July 2026.

Wegovy, Zepbound, Saxenda, Imcivree, Foundayo (orforglipron), Qsymia, Contrave, phentermine, orlistat, and Xenical are absent from every class in the Single PDL. There is no “Anti-Obesity Medications” or “Weight Management Agents” therapeutic class. The PDL covers 19 therapeutic classes; none addresses obesity treatment. This is the operational confirmation of the Pharmacy Manual § 3.7 exclusion at the formulary level.

The sPDL footnote for Incretin Mimetics reads: “Trial of only one agent is required before moving to a non-preferred agent. MSM 1200 - Appendix A section: KK. Incretin Mimetics.” This step-therapy gate applies to T2DM-indication prescriptions only.

Sole Carve-Out: Wegovy CV (Web Announcement 3337)

Nevada Medicaid’s one and only GLP-1 anti-obesity drug coverage pathway is the Wegovy cardiovascular risk-reduction carve-out, established by Web Announcement 3337, dated April 22, 2024. This is the most restrictive Wegovy-CV architecture of any state we have reviewed: no MASH extension, no Zepbound-OSA extension, no Imcivree carve-out — just one carve-out, held static for 19 months through all four SSSB quarterly meetings that followed.

Full verbatim text of Web Announcement 3337:

“Wegovy (semaglutide) Coverage Updates Based on New FDA-Labeled Indication

On March 8, 2024, the FDA announced the approval of a new indication for use of Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in obese or overweight adults with established cardiovascular disease. Wegovy should be used in addition to a reduced calorie diet and increased physical activity.

See the FDA announcement for full recommendations.

Nevada Medicaid has updated policy to include coverage of Wegovy for this new indication in recipients who meet required prior authorization criteria in-line with FDA package labeling.”

Source: Nevada Medicaid Web Announcement 3337, “Wegovy (semaglutide) Coverage Updates Based on New FDA-Labeled Indication,” April 22, 2024. Verified May 2026.

Per Magellan Rx Nevada Medicaid provider portal PA criteria, the Wegovy MACE prior authorization requires ALL of the following:

• Prescribed for risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
• Age ≥ 18 years
• BMI ≥ 27 kg/m²
• Established cardiovascular disease (history of MI, stroke, or symptomatic peripheral arterial disease)
• Patient does NOT have type 1 or type 2 diabetes — patients with T1DM or T2DM must use an alternative therapy; this indication is specific to non-diabetic patients
• PA approval is valid for one year

The “no T1DM/T2DM” gate is critical: a patient with established CVD who also has T2DM cannot use the Wegovy MACE pathway. That patient would need to use an Ozempic or Trulicity (T2DM-indicated) prescription, with the cardiovascular benefit flowing as a secondary effect of diabetes treatment — not as a direct Wegovy MACE authorization.

Nevada’s BMI threshold (≥ 27 kg/m²) matches the FDA’s Wegovy MACE label and is operationally equivalent to Oklahoma’s threshold. This is more permissive than New York’s NYRx PA criteria (which use BMI ≥ 40) but consistent with the FDA label.

What the carve-out does NOT cover:

• Wegovy for noncirrhotic MASH — the FDA approved Wegovy for MASH on August 8, 2025; Nevada has taken no SSSB action as of May 2026
• Zepbound for moderate-to-severe OSA — FDA approved December 20, 2024; Nevada has taken no SSSB action
• Imcivree (setmelanotide) for monogenic obesity — no PA criteria document exists in Nevada Medicaid
• Foundayo (orforglipron) — FDA approved August 14, 2025 for chronic weight management; not on Single PDL

Nevada Health Authority Reorganization (July 1, 2025)

On July 1, 2025, Nevada Medicaid was operationally reorganized under Senate Bill 494 of the 2025 Regular Session, signed by Governor Joe Lombardo June 11, 2025. The Division of Health Care Financing and Policy (DHCFP) became the Nevada Health Authority (NVHA). The full announcement, verbatim from Web Announcement 3661 (July 1, 2025):

“Nevada Health Authority is Official and DHCFP Becomes Nevada Medicaid Effective July 1, 2025

Carson City, NV — We are excited to announce that the Nevada Health Authority (NVHA) is officially on its way with the Governor’s signature on June 11, 2025, to enact Senate Bill 494 and launching on July 1, 2025. The Division of Health Care Financing and Policy can now officially go by its common name Nevada Medicaid.

The goals of this new Department have been resoundingly clear since the beginning: unify similarly aligned agencies to leverage the purchasing power of Medicaid, lower healthcare costs for Nevadans, bring more providers to the state, improve health care quality and streamline Medicaid eligibility.”

Source: Nevada Medicaid Web Announcement 3661, July 1, 2025. Verified May 2026.

NVHA is led by Administrator Stacie Weeks (formerly Nevada Medicaid administrator). NVHA consolidates Nevada Medicaid, Medicaid eligibility (from DWSS), the Patient Protection Commission, Public Employees’ Benefits Program, Silver State Health Insurance Exchange (NevadaHealthLink.com), Office of Analytics, Governor’s Council on Developmental Disabilities, Graduate Medical Education, Waiver Provider Oversight, and Health Care Quality and Compliance.

SB 494 did NOT amend NRS 422.4025 for anti-obesity medication coverage, nor did it alter the Pharmacy Manual § 3.7 categorical exclusion. Legacy regulatory citations to “DHCFP” remain operationally valid. URLs at dhcfp.nv.gov redirect to nevadamedicaid.nv.gov.

Concurrent Dual Transition: January 1, 2026

Nevada is the only state we have reviewed to execute two simultaneous Medicaid operational changes on the same date:

1. Statewide Managed Care Expansion — approximately 75,000 rural Nevadans who were served through fee-for-service (FFS) were enrolled in one of the five MCOs effective January 1, 2026. Rural Nevadans had two MCO choices: CareSource (new entrant, awarded April 2025 — the first new MCO entrant since 2017) and SilverSummit Healthplan (Centene subsidiary).
2. Single PDL Alignment — all five MCOs aligned their formularies to the FFS pharmacy program’s Single PDL effective January 1, 2026, per Web Announcement 3787 (December 10, 2025).

Web Announcement 3787 (December 10, 2025) announced the sPDL transition verbatim:

“Beginning on January 1, 2026, Nevada Medicaid will transition to a Single Preferred Drug List (sPDL) to create a more consistent and streamlined approach to medication coverage. This change is designed to improve access to medications, reduce administrative complexity, and support better coordination of care across all programs. …

Legacy Coverage Period: To support this transition, there will be a temporary coverage period beginning January 1, 2026, through June 30, 2026, allowing members to continue their current prescriptions. This will give time for providers and members to adjust and, when appropriate, switch to a preferred medication.”

Source: Nevada Medicaid Web Announcement 3787, December 10, 2025. Verified May 2026.

The Legacy Coverage Period (January 1 – June 30, 2026) means that any member holding a legacy MCO PA approval for a non-sPDL medication will continue through June 30, 2026 or the original authorization’s expiration date, whichever is earlier. SilverSummit’s single PDL FAQ confirmed: “All prior authorizations that were approved prior to the implementation of a single PDL will be valid through the expiration date on the authorization or 6/30/26, whichever comes first.” After June 30, 2026, the sPDL governs exclusively.

The Five MCOs Effective January 1, 2026

Nevada Medicaid operates five MCOs as of January 1, 2026. All five align their pharmacy formularies to the Single PDL. Key service-area distinctions:

Source: Nevada Medicaid Web Announcement 3753, October 24, 2025. Verified May 2026.

The Health Plan of Nevada Medicaid PDL — the largest urban MCO (UnitedHealthcare subsidiary, Clark County only) — contains the most explicit MCO-level categorical exclusion of any state we have reviewed. Verbatim from its “Plan Exclusions” section:

“PLAN EXCLUSIONS

The following drug categories are excluded from coverage under the outpatient pharmacy benefit and are not part of the Health Plan of Nevada Medicaid PDL.

• DESI drugs
• Anti-obesity agents
• Experimental / research drugs”

Source: Health Plan of Nevada Medicaid PDL “Plan Exclusions” section. Verified May 2026.

HPN’s GLP-1 entries under Antidiabetic Agents list only T2DM-indicated drugs (liraglutide Tier 1, Mounjaro Tier 2, Ozempic Tier 2, Rybelsus Tier 2, Victoza Tier 2 — all with PA + QL). No Wegovy. No Zepbound. No Saxenda.

One notable outlier: Anthem’s NV Medicaid PDLlists ALLI (OTC orlistat 60 mg) with PA, OTC, and QL flags under an “ADHD/Anti-Narcolepsy/Anti-Obesity/ Anorexiants” class header. ALLI is the only anti-obesity agent with a PDL listing at any Nevada MCO. This does NOT constitute Wegovy or Zepbound coverage — it is a legacy OTC listing that predates the current sPDL alignment. The Pharmacy Manual § 3.7 categorical exclusion applies to the state program regardless of this Anthem-specific listing.

PBM: Magellan/Prime Therapeutics

Nevada Medicaid’s FFS pharmacy benefit has been administered by Magellan Medicaid Administration (MMA), a division of Magellan Rx Management (subsequently acquired by Prime Therapeutics in 2022 and now operating as Prime Therapeutics Management LLC), since July 1, 2022. The operational portal is at nv.primetherapeutics.com.

PA contact information (FFS + all five MCOs):

• Phone: 800-695-5526
• PA fax: 844-347-3202
• PA forms / ePA: nv.primetherapeutics.com (CoverMyMeds integration)

Future PBM transition: Section 12 of Chapter 390 of the 2025 Statutes of Nevada (amending NRS 422.4053) authorizes NVHA to contract with a “state pharmacy benefit manager.” This transition has not been executed as of May 2026 — Magellan/Prime Therapeutics remains the operational PBM contractor. The effective date provisions in NRS 422.4025, 422.4032, and 422.4053 are conditioned on the effective date of the initial state-PBM contract, which has not been signed.

SSSB: 19-Month Non-Action Streak on MASH/OSA

The Silver State Scripts Board (SSSB) — Nevada’s Pharmacy and Therapeutics Committee under NRS 422.4035 — meets quarterly and votes on PDL changes. In the four most recent verified quarterly meetings:

• June 20, 2024 (Web Announcement 3387) — no GLP-1 anti-obesity action
• September 26, 2024 (Web Announcement 3458) — added liraglutide generic to Incretin Mimetics (T2DM only); no Wegovy MASH/Zepbound OSA action
• September 18, 2025 (Web Announcement 3757) — no GLP-1 anti-obesity action; this meeting came after the August 8, 2025 FDA Wegovy-MASH approval and the August 14, 2025 FDA Foundayo approval
• December 11, 2025 (Web Announcement 3825) — no GLP-1 anti-obesity action

This 19-month non-action streak (from the April 2024 Wegovy-CV carve-out through December 2025) distinguishes Nevada from Colorado, Oklahoma, Connecticut, and Alabama — all of which added at least one new FDA-label carve-out (MASH or OSA) in 2024–2025. No future SSSB meeting outcomes should be predicted.

SB 244 (2025) Died in Committee

The most significant recent legislative development is the failure of Senate Bill 244 of the 83rd Nevada Legislature (2025 Regular Session) — titled “AN ACT relating to Medicaid; requiring Medicaid to cover certain treatments for obesity and the services of certain programs for the prevention of diabetes.”

Sponsorship (verbatim from enrolled bill):

“SENATE BILL NO. 244 – SENATORS LANGE, NGUYEN, CRUZ-CRAWFORD; FLORES AND TAYLOR — FEBRUARY 26, 2025. Referred to Committee on Health and Human Services.”

Sponsors: Sen. Roberta Lange (D-Las Vegas), Sen. Rochelle Nguyen (D-Las Vegas), Sen. Michelee Cruz-Crawford (D-Las Vegas), Asm. Edgar Flores (D-Las Vegas), Asm. Angela Taylor (D-Las Vegas).

The bill’s operative mandate, verbatim from Section 1:

“1. To the extent that federal financial participation is available, the Director shall include under Medicaid coverage for:

(a) Treatment for obesity, including, without limitation, coverage of:

(1) Intensive health, behavior and lifestyle treatment; and

(2) Any surgical intervention included in the most current Guidelines on Indications for Metabolic and Bariatric Surgery published by the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders; and

(b) The services of a diabetes prevention program for recipients of Medicaid …”

Section 2 amended NRS 422.4025 to add a new subsection (4)(c), verbatim:

“(c) Prescription drugs approved by the United States Food and Drug Administration with an indication for chronic weight management in patients who have been diagnosed with obesity.”

Section 2 subsection (8) added the operative coverage mandate:

“8. The Medicaid program must cover the drugs described in paragraph (c) of subsection 4 to the extent that such drugs are prescribed in accordance with the indications of the United States Food and Drug Administration.”

Section 5 set an effective date of January 1, 2026 — the same date as the statewide MCO expansion and the Single PDL.

Source: SB 244 enrolled text, 83rd Nevada Legislature (2025 Regular Session). Verified May 2026.

Why it failed:

The Nevada Division of Health Care Financing and Policy (DHCFP) projected the bill would cost $165.4 million over the 2025–2027 biennium— with $64.3 million from the Nevada General Fund and approximately $101.1 million in federal share. The bill died in money committee on June 3, 2025without reaching a floor vote.

Senate HHS Committee Chair Sen. Fabián Doñate expressed reservations about pharmaceutical-industry influence and prescribing guardrails (per Nevada Current, March 19, 2025):

“How can we ensure there are guardrails up, that the prescriptive treatments are actually medically necessary versus saying that any doctor can just recommend?”

“If I’m a pharmaceutical company and a state were to pass this requirement, the first thing I would do is send as many representatives that I could.”

Dr. Steven Shane, pediatric obesity specialist at Renown Children’s Hospital (testifying March 19, 2025), described the clinical stakes:

“I typically cannot provide the best evidence-based therapies because Medicaid does not cover these options.”

“It is no different than not covering other diseases such as asthma, diabetes or even cancer.”

No 2026 successor legislation has been introduced as of May 2026.

Appeals: NHA Fair Hearings

Nevada Medicaid members denied a GLP-1 prescription have two primary administrative remedies:

1. MCO internal appeal — for members in any of the five MCOs. Must be filed within 60 days of the MCO’s adverse action notice. The MCO must issue a decision within 45 days (standard) or 3 days (expedited clinical urgency).
2. Nevada Health Authority Fair Hearing — available after an adverse MCO appeal decision, or for FFS-served members after a PA denial. Request must be filed within 90 days of the adverse action. Fair hearings are conducted by the NVHA Hearings Office (formerly DHCFP Office of Administrative Hearings). Judicial review follows under NRS Chapter 233B (Administrative Procedures Act).

Practical guidance for Wegovy MACE appeals: If a member meets all criteria (age ≥ 18, BMI ≥ 27, established CVD, no T1DM/T2DM) but received a denial, the most likely cause is incomplete documentation. Resubmit with verbatim chart documentation of the prior MI, stroke, or symptomatic PAD event plus a clear indication statement. Contact Prime Therapeutics PA line (800-695-5526) to clarify documentation requirements before filing a formal appeal.

For chronic-weight-management denials: No operational PA pathway exists. The categorical exclusion applies categorically. The only remaining options are a pediatric EPSDT case-by-case medical-necessity exception (applicable only to members under 21) or waiting for a future legislative or SSSB action. For strategies applicable when any insurer drops GLP-1 coverage, see the GLP-1 insurance dropped-coverage appeal playbook.

How Nevada Compares: Most Restrictive Wegovy-CV State

Of the five states we have reviewed that cover Wegovy for the MACE indication, Nevada’s architecture is the most restrictive:

NY and NV are structurally the closest analogs: both have a Wegovy-CV-only DUR-Board carve-out layered over a categorical exclusion. Key differences: NY’s exclusion is anchored at the regulatory level (18 NYCRR § 505.3(g)(3)); NV’s is at the Pharmacy Manual level. NY requires BMI ≥ 40 for MACE (stricter than the FDA label and than NV’s ≥ 27); NY also covers Imcivree for monogenic obesity while NV does not.

WA is the closest operational analog on the “covers-Wegovy-CV-but-not-general-weight-management” dimension. WA’s coverage is broader (MACE + MASH + Zepbound OSA); NV’s is more restrictive (MACE only). Both are Medicaid programs that a naive KFF-read might miscategorize. As noted, Washington Apple Health appears on the KFF covering list despite its operational exclusion; Nevada is not.

AL is the closest analog on exclusion architecture with two carve-outs. NV is structurally one carve-out behind AL — NV has MACE, AL has MACE plus Zepbound-OSA. NV’s exclusion is Pharmacy Manual level; AL’s is regulatory (Ala. Admin. Code r. 560-X-16-.01(2)(b)).

What Nevada Medicaid Patients Can Do in 2026

1. Confirm your MCO. Call the NVHA member line (Medicaid@nvha.nv.gov) or visit nevadamedicaid.nv.gov to confirm your plan. If you are a rural member who transitioned on January 1, 2026, your MCO is either CareSource (833-230-2058) or SilverSummit (844-366-2880).
2. If you have established CVD (prior MI, stroke, or symptomatic PAD) AND no diabetes: Ask your prescriber to submit a Wegovy MACE prior authorization via Prime Therapeutics (phone 800-695-5526, fax 844-347-3202, or ePA at nv.primetherapeutics.com). Provide documented chart evidence of your CVD history.
3. If you have type-2 diabetes: Ozempic (semaglutide injection), Trulicity, Victoza, and Rybelsus are covered as Preferred agents on the Single PDL. Mounjaro (tirzepatide) is covered as a non-preferred agent with PA and clinical criteria (trial of one preferred agent required). The cardiovascular benefit of these agents flows through the T2DM indication.
4. If you are seeking coverage for chronic weight management only: No operational pathway exists in Nevada Medicaid as of May 2026. Consider exploring whether your provider’s practice has access to Novo Nordisk’s or Eli Lilly’s patient assistance programs, or telehealth providers with sliding-scale pricing — our cheapest semaglutide providers ranking and GLP-1 pricing index track the lowest current cash rates.
5. Monitor SSSB meeting schedules. The Silver State Scripts Board meets quarterly. A future SSSB action could add Wegovy-MASH or Zepbound-OSA carve-outs without legislative action. SSSB meeting announcements are published at nevadamedicaid.nv.gov.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• Top compounded vs brand GLP-1 questions on Reddit, answered
• GLP-1 contraindications cheat sheet

Sources

1. Nevada Medicaid and Nevada Check Up Pharmacy Manual, Section 3.7 “Covered and Non-Covered Drugs.” Prime Therapeutics Management LLC. nv.primetherapeutics.com. Verified May 2026.
2. Nevada Medicaid Single Preferred Drug List (sPDL), effective November 1, 2025. Section 148B Incretin Mimetics and Combinations. nv.primetherapeutics.com/cms/nvm/static-assets/documents2/pdl/NV_SPDL_11.01.25.pdf. Verified May 2026.
3. Nevada Medicaid Web Announcement 3337, “Wegovy (semaglutide) Coverage Updates Based on New FDA-Labeled Indication,” April 22, 2024. medicaid.nv.gov/Downloads/provider/web_announcement_3337_20240422.pdf. Verified May 2026.
4. Nevada Medicaid Web Announcement 3787, “Nevada Medicaid is Implementing a Single Preferred Drug List (sPDL),” December 10, 2025. medicaid.nv.gov/Downloads/provider/web_announcement_3787_20251210.pdf. Verified May 2026.
5. Nevada Medicaid Web Announcement 3661, “Nevada Health Authority is Official and DHCFP Becomes Nevada Medicaid Effective July 1, 2025,” July 1, 2025. medicaid.nv.gov/Downloads/provider/web_announcement_3661_20250701.pdf. Verified May 2026.
6. Nevada Medicaid Web Announcement 3753, “Statewide Managed Care Questions and Answers,” October 24, 2025. medicaid.nv.gov/Downloads/provider/web_announcement_3753_20251024.pdf. Verified May 2026.
7. Nevada Medicaid Web Announcement 3757, Silver State Scripts Board changes effective November 1, 2025. Verified May 2026.
8. Nevada Medicaid Web Announcement 3825, Silver State Scripts Board changes effective February 1, 2026. Verified May 2026.
9. Health Plan of Nevada Medicaid PDL, “Plan Exclusions” section. myhpnmedicaid.com/content/dam/hpnv-public-sites/myhpnmedicaid/documents/provider/nv-provider-pdl.pdf. Verified May 2026.
10. SilverSummit Healthplan Single PDL FAQ. silversummithealthplan.com. Verified May 2026.
11. Senate Bill 244, 83rd Nevada Legislature (2025 Regular Session). Enrolled text. archive.leg.state.nv.us/Session/83rd2025/Bills/SB/SB244.pdf. Verified May 2026.
12. Senate Bill 494, 83rd Nevada Legislature (2025 Regular Session). Nevada Health Authority Act. Signed June 11, 2025; effective July 1, 2025. Verified May 2026.
13. 42 U.S.C. § 1396r-8(d)(2)(A). Federal optional exclusion authority for “Agents when used for anorexia, weight loss, or weight gain.” Cornell LII, law.cornell.edu. Verified May 2026.
14. NRS 422.4025 (“The Department shall, by regulation, develop a list of preferred prescription drugs”). Nevada Revised Statutes. leg.state.nv.us. Verified May 2026.
15. NRS 422.4035, 422.405. Silver State Scripts Board statutory authority. Verified May 2026.
16. Nevada Current, March 19, 2025. Senate Health and Human Services Committee testimony on SB 244. Sponsoring-senator and Sen. Doñate verbatim quotes. Verified May 2026.